About us

History

Our history is written day by day, thanks to the vision of our shareholders and the talent of our employees. We care about your health and quality of life.


March 1974

Stendhal is created as a pharmaceutical company.


1997

Acquisition

A group of Mexican investors acquires Stendhal. A comprehensive transformation takes place: our philosophy and business mission are renewed, shaping us into the company we are today.


2003

Major changes

The manufacturing site is remodeled following the highest world-class standards. The first product line for the treatment of HIV/AIDS is launched. The HIV Business Unit is created.


2008

Neurology and Neurosciences

We delve into Neurology, launching the first monoclonal antibody for the treatment of multiple sclerosis. The Neurosciences Business Unit is created.


2009

Stendhal Americas

Stendhal partners with Eicopen Pharma, reaching out to countries in Central America and the Andean Region.


2010-2011

Stendhal leader in innovative therapies

Stendhal becomes the indisputable leader in the treatment of HIV/AIDS and Multiple Sclerosis thanks to innovative therapies in areas such as critical care and genetic disorders and diseases.


2013-2014

Cardiovascular Portfolio

Trade agreements are initiated to include cardiovascular molecules in our portfolio. The Cardiovascular Business Unit is created, and we launch our first molecule for Arterial Hypertension.


2015

Rise to the Top

Stendhal secures its spot in various national rankings as one of the most important pharmaceutical companies in Mexico.


2017

Central Nervous System and Oncology

Dimethyl fumarate, an innovative treatment for Multiple Sclerosis, is incorporated into our product portfolio.

Work begins on new molecules for advanced Oncology therapy.


2019

Stendhal forges a strategic alliance to increase the distribution and outreach of Primary Care products in Mexico, Central America, and the Caribbean.


2020

Methoxyflurane is added to the portfolio for acute, moderate, or severe pain; it contributes to the effective and safe treatment of patients.

Business Development

In Stendhal we generate shared value, we develop long-term alliances strengthening our portfolio to meet the health needs of the region.

Join the Team

We are open to professionals with a high level of initiative, with the capacity to transform uncertainty into opportunities.


Logotipo

© Stendhal International 2022 All Rights Reserved
Stendhal Pharma is property of Específicos Stendhal, S.A. de C.V.

Follow us: